Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

ObjectiveIn clinical trials (CTs), the assessment of minimal residual disease (MRD) has proven to have prognostic value for multiple myeloma (MM) patients. Multiparameter flow cytometry (MFC) and next-generation sequencing are currently used in CTs as effective tools for outcome prediction. We have...

Full description

Bibliographic Details
Main Authors: Veronika Riebl, Sandra Maria Dold, Dagmar Wider, Marie Follo, Gabriele Ihorst, Johannes M. Waldschmidt, Johannes Jung, Michael Rassner, Christine Greil, Ralph Wäsch, Monika Engelhardt
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
minimal residual disease
multiple myeloma
multiparameter flow cytometry
improved progression-free survival
phenotypic analyses
bone marrow
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.708231/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.708231/full

Similar Items